[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab. Radiol Oncol. 2020;54(3):285-294. Accessed October 12, 2026. https://radioloncol.com/index.php/ro/article/view/3452